Suscribirse

Relationship between 25-Hydroxyvitamin D and All-cause and Cardiovascular Disease Mortality - 18/05/13

Doi : 10.1016/j.amjmed.2012.11.021 
Muhammad Amer, MD, MHS, FACP , Rehan Qayyum, MD, MHS
Department of Medicine, Johns Hopkins University, Baltimore, Md 

Requests for reprints should be addressed to Muhammad Amer, MD, Johns Hopkins University, 600 North Wolfe Street, Osler 264, Baltimore, MD 21287

Abstract

Background

Observational studies have suggested a strong relationship between 25(OH)D and all-cause and cardiovascular disease mortality. A few studies also have described a nonlinear trend for this relationship in population subgroups, but less is known about this relationship in healthy adults. We examined the presence of a nonlinear relationship between 25(OH)D and all-cause and cardiovascular disease mortality among healthy adults.

Methods

We examined 10,170 participants (≥18 years of age) using National Health and Nutrition Examination Survey data (2001-2004) combined with National Death Index for vital status information through December 2006. Cox proportional hazard models with spline (single knot at population median of 25[OH]D) were fit to estimate hazard ratios (HRs) for all-cause and cardiovascular disease mortality for each 10-unit increase in serum 25(OH)D. Models were adjusted for demographic and conventional cardiovascular disease risk factors.

Results

Mean age of study participants was 46.6 (20.5) years, while median (interquartile range) 25(OH)D was 21 (15-27) ng/mL. After a median follow-up of 3.8 years (range 2.8-4.9), 509 all-cause and 184 cardiovascular diseases-related deaths were observed. In univariate analysis, 25(OH)D decreased hazards of all-cause (HR 0.59; 95% confidence interval [CI], 0.45-0.77) and cardiovascular disease (HR 0.56; 95% CI, 0.38-0.82) mortality below but not above its population median. In adjusted models, 25(OH)D retained the inverse association for all-cause (HR 0.54; 95% CI, 0.35-0.84) and cardiovascular disease (HR 0.50; 95% CI, 0.26-0.98) mortality below but not above its population median.

Conclusions

We found an inverse association between 25(OH)D and all-cause and cardiovascular disease mortality in healthy adults with serum 25(OH)D levels of ≤21 ng/mL. Clinical trials for the primary prevention of cardiovascular disease with 25(OH)D supplementation may target healthy adults with serum 25(OH)D levels of ≤21 ng/mL to validate these findings.

El texto completo de este artículo está disponible en PDF.

Keywords : All-cause mortality, Cardiovascular disease mortality, NHANES, 25(OH)D, Vitamin D


Esquema


 Funding: Rehan Qayyum was supported by National Institute of Health grant No. 1K23HL105897-01.
 Conflict of Interest: None.
 Authorship: Both authors had access to the data and a role in writing the original manuscript.


© 2013  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 126 - N° 6

P. 509-514 - juin 2013 Regresar al número
Artículo precedente Artículo precedente
  • Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension
  • Michael A. Weber, George L. Bakris, Allen Hester, Matthew R. Weir, Tsushung A. Hua, Dion Zappe, Bjorn Dahlof, Eric J. Velazquez, Bertram Pitt, Kenneth Jamerson
| Artículo siguiente Artículo siguiente
  • Prevalence, Extent, and Independent Predictors of Silent Myocardial Infarction
  • Nisha Arenja, Christian Mueller, Niklas F. Ehl, Miriam Brinkert, Katharina Roost, Tobias Reichlin, Seoung Mann Sou, Thomas Hochgruber, Stefan Osswald, Michael J. Zellweger

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.